We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PBX Probiotix Health Plc

0.00 (0.00%)
17 May 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
Probiotix Health Plc AQSE:PBX Aquis Stock Exchange Ordinary Share GB00BLNBFR86
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.25 3.00 6.00 4.50 4.25 4.25 0.00 15:29:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Probiotix Health Share Discussion Threads

Showing 126 to 146 of 150 messages
Chat Pages: 6  5  4  3  2  1
Is that so they can buy more?
ming da merciless

Corporate: The Company aim will continue to work with AQUIS and
explore opportunities on other markets, including AIM, to increase liquidity
in ProBiotix shares.

ming da merciless
A reminder of what they predicted (ramped) for 2023


Commercial Activity 2023: The Company reports early indications for
2023 show another year of strong growth including the potential for:-


Extension of product ranges and territories with the Company's two
largest partners, AlfaSigma and Seed Health.


The launch of CholBiome® products in Brazil with Ayalla, following
an 18 month registration period, with a health claim for cardiovascular
health. The Company believes that LP(LDL)® will be the first probiotic strain
ever to be registered in Brazil for cardiovascular health, with first-mover
benefits and strong interest from the pharmaceutical industry.


New product launches in Hong Kong, Germany and on TMAll in China.
A number of these from companies who have already placed orders with delivery
in 2023.


One or more agreements with large US partners creating the
opportunity for substantive revenue growth. This will be supported by the
expansion of our CholBiome® range with a phytosterol-containing product with
US health claims.


Continued strong growth in e-commerce sales with anticipated revenues
of £250K to £500K


Scientific Update: The Company continues its scientific studies to
support sales and marketing efforts with scientific presentations and
publications and developing the product pipeline. This can be through
exploring new probiotic strains and/or extending the applications and use of
LP(LDL)®. Current studies include human studies investigating the impact of
LP(LDL)® on sleep, stress, and anxiety, and the reduction of cholesterol in
coeliac disease. Sleep aids and stress management products are the fastest
growing category within healthcare (Goldstein Market Intelligence, 2020) and
this is another step in extending the range of applications for our
scientifically and clinically proven products into large growing markets where
there is an unmet clinical need. The Company has had three abstracts
accepted for presentation as posters and/or oral presentations at ProBiota in
February 2023.


Corporate: The Company aim will continue to work with AQUIS and
explore opportunities on other markets, including AIM, to increase liquidity
in ProBiotix shares.

The Company sees 2023 as a year of opportunity and continued growth and
operational profitability, with a focus on commercialising products across
more territories, particularly the USA with larger partners, and increasing
the proportion of final product to ingredient sales to partners and via our
e-commerce platform. This will be supported by a developing product pipeline
with new probiotic strains and extending the applications and use of LP(LDL)®
into new areas, all supported by strong science and human studies.

The scale of the market opportunity in probiotics is large, particularly
outside the traditional gut health and health and wellbeing markets, where
growth is slowing. This is increasing interest in ProBiotix and its products
from larger partners looking to sustain future growth. The proven safety and
efficacy of our products, the substantial scope for expansion of our range and
geography, and the appointment of a proven commercial industry leader, allow
us to look to 2023 with confidence and enthusiasm.

pj 1
Just trying to figure out the market cap value they put on it in 2018 via cln yield and discounts etc etc

Anyway listed at MC circa 20 million?

Currently around 5-6 million?

Looking at its net operational cashflows, and giving some weight to analysis via same of opti and sbtx over time, isn't this still overvalued by 5_6 million when you deduct forecasted cashburn ?

Just have to hope it can do an opti and consistently have revenues with a hefty gearing towards imaginary sales

We just need to ignore matching real costs

institutional investments
I'm a bit confused with regards to ownership of stock here

The CLN at opti in 2018 re a raise for around a million. What weight of the float does that represent?

institutional investments
Peterhouse Capital Limited

On one of my databases. Everything is subjective without providing the statistics so, best to look at overall performance of shares they were appointed for over a period, how many raises followed etc...where the SPs are all at now and of course, do a spike count.

Not that broker selection should be a predictor of future investor gains or losses of course

institutional investments
Unfortunately that probiotix seems to have few sales given review counts on other products
institutional investments
This was clever actually

The claim of every batch tested to ensure athlete friendly, when it all it basically is, Is a glutamine capsule falling under food supplement category 😂

institutional investments
It's sort of like @Unofficial Convertibles.. Just nktvneed new issue
institutional investments
Just be wary of the foward sells with newly appointed . to 3rd P. They can just work price straight down for a stack, working news without needing a rise Just liquidity. I'm sure u know how to spot that anyway. Can short medium to long term
institutional investments
If you database all nomads and makers involved in the three since inception, you can make a good stack monitoring for spike plays eleawwhrre. Might as well

I've got a database of over 4 spreadsheets from AIM and lower.When no sign of a job currently on one, you know they are about to collect elsewhere lol

institutional investments
I've bot been keeping tabs. They will want all this on an norw open/liquid market for easy dumping so once they start talking about that, it's a sign
institutional investments
I do hope sales are growing here at a faster rate than over at Opti but who knows as no one has bothered issuing any figures for either.
JMF6920 Apr '24 - 17:42 - 101 of 103
0 0 0
It appears that the only time we will get an indication of sales for 2023 will be when the results are announced in June.


At least it shows that they are thinking about standard shareholders and deciding not to disappoint them beforehand

institutional investments
Agree. Annoying. Frustrating. Esp as 5 of the PBX team will be at trade fayre/show in Geneva for 3 days in May.(See LinkedIn).

We know Steen is adding to staff to hopefully increase sales. Just give us an idea of how sales are going.

Same as OPTI? Its very poor imo, especially after all the bluster
pj 1
It appears that the only time we will get an indication of sales for 2023 will be when the results are announced in June.
Maybe in reality our products are no different to what's already out there in a saturated market?
pj 1
Still no sign of any updates
I have to agree with you. Newsflow has been next to non-existent.

However, OHara is not in charge here. That will be down to Steen Anderson.

SOH assured a regular update of positive news flow in PBX

We should have known better.

pj 1
Chat Pages: 6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock